TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05361941: Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

Sponsor: Elute, Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 204 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,764,000

Rescue Site Savings

+$1,176,000

Unlock Full NCT05361941 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05361941 Rescue Dossier →